results in lower treatment-related costs over 5 years than later diagnosis.The study enrolled 431 patients in the Leiden Early Arthritis Clinic at the Leiden University Medical Center, Leiden, the Netherlands.Early treatment was defined as a symptom duration 12 weeks.
Prescription data from patient records and 2022 disease-modifying antirheumatic drug prices were used to determine overall costs over 5 years. Autoantibody-negative and autoantibody-positive RA were studied separately due to possible differences in disease severity.In the 165 patients with autoantibody-negative RA, late treatment was associated with 316% higher costs over 5 years than early treatment .In the 43 patients with autoantibody-positive RA only prescribed biologics, late treatment was associated with 46% higher costs than early treatment.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WTVYNews4 - 🏆 590. / 51 Read more »
Source: IntEngineering - 🏆 287. / 63 Read more »
Source: physorg_com - 🏆 388. / 55 Read more »